The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Treatment challenges for young CLL patients
Treating young patients with chronic lymphocytic leukemia (CLL) poses a unique set of challenges because treatment has to be effective for many years, and even decades. Matthew Davids, MD, MSc, of the Dana-Farber Cancer Institute, Boston, MA spoke to us about these challenges at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. Here, he discusses the risk of resistance mutations and toxicity when young patients are given long-term monotherapies, and points to combination therapies incorporating novel agents as the way forward in this patient group.
